Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
Predictive Factors of Intracranial Response of Immune Checkpoint Inhibitors in Patients with Brain Metastasis from Non-Small Cell Lung Cancer
Assistance Publique Hopitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, Marseille, France
,
Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
,
Assistance Publique Hopitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Mar-seille University, Marseille, France
,
Assistance Publique Hopitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Mar-seille University, Marseille, France
,
Public Health, Chronic Diseases and Quality of Life: Research Unit, Aix Marseille University, Marseille, France
,
Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
,
Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
,
Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
1 Assistance Publique Hopitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Marseille University, Marseille, France
2 Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
3 Assistance Publique Hopitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Mar-seille University, Marseille, France
4 Assistance Publique Hopitaux de Marseille, Department of Multidisciplinary Oncology and Therapeutic Innovations, Aix Mar-seille University, Marseille, France
5 Public Health, Chronic Diseases and Quality of Life: Research Unit, Aix Marseille University, Marseille, France
6 Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
7 Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
8 Centre de Recherche en Cancérologie de Marseille (CRCM), Marseille, France
Background: Immune checkpoint inhibitors (ICI)s were recently approved for the treatment of advanced non-small cell lung cancer (NSCLC). Whereas brain metastases (BM) are frequent in NSCLC patients, data are missing regarding ICIs intracranial efficacy and tolerance in patients with BM from NSCLC . Methods: This retrospective study was performed in the Multidisciplinary Oncology and Therapeutic Innovation department, Marseille, France between April 2013 and February 2016. Data from patients with NSCLC with at least one BM, and treated with ICIs (anti-PD1, anti-PDL1 or anti-CTL4) were analyzed. Clinical, biological data and outcomes were retrieved from electronic patients’ records. We assessed ICIs intracranial efficacy and tolerance. Results: Data from 55 patients were analyzed. Objective Response Rate (ORR) and Disease Control Rate (DCR) were respectively of 1.8 and 36.4%. Median overall survival was 17.2 months and median progression free survival was 2.9 months. Intracranial ORR (icORR) and intracranial DCR (icDCR) were respectively 16.4% and 45.5%. Both were independent of smoking status, intracranial treatment, performance status, pathology, molecular profile and the presence or number of BM at diagnosis. However, there was a trend towards an association between icORR and ECOG PS (p = 0.05), tobacco status (p = 0.057) and intracranial treatment. Adverse events were seen in 38.2% patients without identified predictive factor. Neurological symptoms appeared in 5.5% patients during immunotherapy and improved in 3.63% patients. Conclusions: ICIs can be used safely on patients with BM from NSCLC. However, intracranial response is heterogeneous in such patients and we showed ECOG PS, tobacco smoking and intracranial treatment to be associated with an improved icORR. This is the first study looking for predictive factors of intracranial response of ICIs in patients with BM from NSCLC.
Taillibert, S. and Le Rhun, é. (2015) Epidemiology of Brain Metastases. Cancer/Radiothérapie, 19, 3-9. https://doi.org/10.1016/j.canrad.2014.11.001
Salbeck, R., Grau, H.C. and Artmann, H. (1990) Cerebral Tumor Staging in Patients with Bronchial Carcinoma by Computed Tomography. Cancer, 66, 2007-2011. https://doi.org/10.1002/1097-0142(19901101)66:9 3.0.CO;2-C
Zimm, S., Wampler, G.L., Stablein, D., Hazra, T. and Young, H.F. (1981) Intracerebral Metastases in Solid-Tumor Patients: Natural History and Results of Treatment. Cancer, 48, 384-394. https://doi.org/10.1002/1097-0142(19810715)48:2 3.0.CO;2-8
Deeken, J.F. and Loscher, W. (2007) The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses. Clinical Cancer Research, 13, 1663-1674. https://doi.org/10.1158/1078-0432.CCR-06-2854
Kim, J.-E., Lee, D.H., Choi, Y., Yoon, D.H., Kim, S.-W., Suh, C. and Lee, J.-S. (2009) Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as a First-Line Therapy for Never-Smokers with Adenocarcinoma of the Lung Having Asymptomatic Synchronous Brain Metastasis. Lung Cancer, 65, 351-354. https://doi.org/10.1016/j.lungcan.2008.12.011
Barlesi, F., Spano, J.-P., Cortot, A.B., Carpentier, A.F., Robinet, G. and Besse, B. (2015) Systemic Treatment of Brain Metastases from Lung Cancer. Cancer/Radiothérapie, 19, 43-47. https://doi.org/10.1016/j.canrad.2014.12.001
Besse, B., Le Moulec, S., Mazières, J., Senellart, H., Barlesi, F., Chouaid, C., et al. (2015) Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. Clinical Cancer Research, 21, 1896-1903. https://doi.org/10.1158/1078-0432.CCR-14-2082
Ribas, A. (2012) Tumor Immunotherapy Directed at PD-1. The New England Journal of Medicine, 366, 2517-2519. https://doi.org/10.1056/NEJMe1205943
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 1627-1639. https://doi.org/10.1056/NEJMoa1507643
Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E.E., Poddubskaya, E., et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 373, 123-135. https://doi.org/10.1056/NEJMoa1504627
Herbst, R.S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J.L., Han, J.-Y., et al. (2016) Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial. The Lancet, 387, 1540-1550. https://doi.org/10.1016/S0140-6736(15)01281-7
Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csoszi, T., Fülop, A., et al. (2016) Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 375, 1823-1833. https://doi.org/10.1056/NEJMoa1606774
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., et al. (2018) Pembrolizumab Plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. The New England Journal of Medicine, 378, 2078-2092. https://doi.org/10.1056/NEJMoa1801005
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüs, M., Mazières, J., et al. (2018) Pembrolizumab Plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. The New England Journal of Medicine, 379, 2040-2051. https://doi.org/10.1056/NEJMoa1810865
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., et al. (2016) Atezolizumab versus Docetaxel in Patients with Previously Treated Non-Small-Cell Lung Cancer (OAK): A Phase 3, Open-Label, Multicentre Randomised Controlled Trial. The Lancet, 389, 255-265. https://doi.org/10.1016/S0140-6736(16)32517-X
Ransohoff, R.M. and Engelhardt, B. (2012) The Anatomical and Cellular Basis of Immune Surveillance in the Central Nervous System. Nature Reviews Immunology, 12, 623-635. https://doi.org/10.1038/nri3265
Berghoff, A., Inan, C. and Ricken, G. (2014) Tumor-Infiltrating Lymphocytes (TILs) and PD-L1 Expression in Non-Small Cell Lung Cancer Brain Metastases (BM) and Matched Primary Tumors (PT). Annals of Oncology, 25, iv465-iv466. https://doi.org/10.1093/annonc/mdu349.103
Goldberg, S.B., Gettinger, S.N., Mahajan, A., Chiang, A.C., Herbst, R.S., Sznol, M., et al. (2016) Pembrolizumab for Patients with Melanoma or Non-Small-Cell Lung Cancer and Untreated Brain Metastases: Early Analysis of a Non-Randomised, Open-Label, Phase 2 Trial. The Lancet Oncology, 17, 976-983. https://doi.org/10.1016/S1470-2045(16)30053-5
Rizvi, N.A., Mazières, J., Planchard, D., Stinchcombe, T.E., Dy, G.K., Antonia, S.J., et al. (2015) Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Trial. The Lancet Oncology, 16, 257-265.
Karim, S. and Leighl, N. (2016) Pembrolizumab for the Treatment of Thoracic Malignancies: Current Landscape and Future Directions. Future Oncology, 12, 9-23. https://doi.org/10.2217/fon.15.294
Rahman, R., Cortes, A., Niemierko, A., Oh, K.S., Flaherty, K.T., Lawrence, D.P., Sullivan, R.J. and Shih, H.A. (2018) The Impact of Timing of Immunotherapy with Cranial Irradiation in Melanoma Patients with Brain Metastases: Intracranial Progression, Survival and Toxicity. Journal of Neuro-Oncology, 138, 299-306. https://doi.org/10.1007/s11060-018-2795-7
Lehrer, E.J., Peterson, J., Brown, P.D., Sheehan, J.P., Quinones-Hinojosa, A., Zaorsky, N.G. and Trifiletti, D.M. (2019) Treatment of Brain Metastases with Stereotactic Radiosurgery and Immune Checkpoint Inhibitors: An International Meta-Analysis of Individual Patient Data. Radiotherapy and Oncology, 130, 104-112. https://doi.org/10.1016/j.radonc.2018.08.025
Choong, E.S., Lo, S., Drummond, M., Fogarty, G.B., Menzies, A.M., Guminski, A., et al. (2017) Survival of Patients with Melanoma Brain Metastasis Treated with Stereotactic Radiosurgery and Active Systemic Drug Therapies. European Journal of Cancer, 75, 169-178. https://doi.org/10.1016/j.ejca.2017.01.007
Silk, A.W., Bassetti, M.F., West, B.T., Tsien, C.I. and Lao, C.D. (2013) Ipilimumab and Radiation Therapy for Melanoma Brain Metastases. Cancer Medicine, 2, 899-906. https://doi.org/10.1002/cam4.140
Du Four, S., Wilgenhof, S., Duerinck, J., Michotte, A., Van Binst, A., De Ridder, M. and Neyns, B. (2012) Radiation Necrosis of the Brain in Melanoma Patients Successfully Treated with Ipilimumab, Three Case Studies. European Journal of Cancer, 48, 3045-3051. https://doi.org/10.1016/j.ejca.2012.05.016
Stokes, W.A., Binder, D.C., Jones, B.L., Oweida, A.J., Liu, A.K., Rusthoven, C.G. and Karam, S.D. (2017) Impact of Immunotherapy among Patients with Melanoma Brain Metastases Managed with Radiotherapy. Cancer Immunology Research, 313, 118-122. https://doi.org/10.1016/j.jneuroim.2017.10.006
Tawbi, H.A., Forsyth, P.A., Algazi, A., Hamid, O., Hodi, F.S., Moschos, S.J., et al. (2018) Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. The New England Journal of Medicine, 379, 722-730. https://doi.org/10.1056/NEJMoa1805453
Cohen, J.V., Alomari, A.K., Vortmeyer, A.O., Jilaveanu, L.B., Goldberg, S.B., Mahajan, A., et al. (2016) Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab Treatment. Cancer Immunology Research, 4, 179-182. https://doi.org/10.1158/2326-6066.CIR-15-0160
Qian, J.M., Mahajan, A., Yu, J.B., Tsiouris, A.J., Goldberg, S.B., Kluger, H.M. and Chiang, V.L.S. (2017) Comparing Available Criteria for Measuring Brain Metastasis Response to Immunotherapy. Journal of Neuro-Oncology, 132, 479-485. https://doi.org/10.1007/s11060-017-2398-8
Hamilton, A. and Sibson, N.R. (2013) Role of the Systemic Immune System in Brain Metastasis. Molecular and Cellular Neuroscience, 53, 42-51. https://doi.org/10.1016/j.mcn.2012.10.004
Tomasini, P., Serdjebi, C., Khobta, N., Metellus, P., Ouafik, L., Nanni, I., et al. (2016) EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 17, 2132. https://doi.org/10.3390/ijms17122132
Long, G.V. and Margolin, K.A. (2013) Multidisciplinary Approach to Brain Metastasis from Melanoma: The Emerging Role of Systemic Therapies. 2013 ASCO Educational Book Meeting, Chicago, IL, 31 May-4 June 2013, 393-398. https://doi.org/10.1200/EdBook_AM.2013.33.393